HC Wainwright Rates Opus Genetics (IRD) buy, $8 Price Target
Analyst Matthew Caufield keeps a buy rating and an $8.0 price target on Opus Genetics, a 96.80% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated Opus Genetics, Inc. ($IRD) "buy" with a $8 price target on June 17, 2026.
Since the rating, $IRD is down 8.6% after 1 week, down 19.5% after 1 month and down 5.4% to date (from the $4.06 close on Jun 17, 2026).
IRD
Opus Genetics, Inc.
Key Points
- HC Wainwright analyst Matthew Caufield reiterated a buy rating on Opus Genetics, Inc. (NasdaqCM: IRD) with an $8.00 price target on June 17, 2026.
- HC Wainwright's $8 price target implies 96.80% upside from Opus Genetics, Inc.'s ($IRD) current $4.07 share price.
- The stock traded around $4.07, sitting well above its 52-week low of $1.50 and below its high of $7.07.
- The broader analyst community holds a strong buy consensus with 17 analyst opinions and a mean price target of $13.00.
Get $IRD trade alerts by text
We text you when insiders, Congress or big funds trade $IRD. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Opus Genetics, Inc. alert may contain errors. Disclosures
Analysts Set New Price Targets
HC Wainwright analyst Matthew Caufield reiterated a buy rating on Opus Genetics, Inc. (NasdaqCM: IRD) on June 17, 2026, keeping the firm's price target at $8.00. The note comes as the biotech firm advances its clinical-stage pipeline of gene therapies targeting inherited retinal diseases.
Opus Genetics Stock Position
Shares of Opus Genetics traded at $4.07 recently, positioned near its 50-day moving average of $4.06 and above its 200-day moving average of $3.87. The biotech stock has recorded a 52-week low of $1.50 and a 52-week high of $7.07, backed by a market capitalization of roughly $434.3 million. The company reports a beta of 0.58.
$IRD price target
Opus Genetics, Inc. daily closes and this analyst's $8 target. Not advice.
Analysts Set New Price Targets
Wall Street firms maintain an active coverage map for the company, featuring several recent updates from major financial institutions. On October 16, 2026, Citizens reiterated a Market Outperform rating with a $17.00 price target. Jones Trading maintained a buy rating on October 6, 2026, and raised its target to $17.00 from $10.00. Chardan Capital kept a buy rating on October 2, 2026, setting a $16.00 target. Wedbush maintained its outperform rating on September 10, 2026, lifting its target to $13.00 from $10.00, while Oppenheimer maintained an outperform rating on September 9, 2026, raising its target to $20.00 from $10.00. Additional notes on September 9, 2026, included an HC Wainwright & Co. reiteration at an $8.00 target, a BTIG buy reiteration at a $12.00 target, and Chardan Capital maintaining a buy rating with a $16.00 target. Across 17 analyst opinions, the consensus view stands at a strong buy with a mean price target of $13.00, ranging from a low of $8.00 to a high of $20.00.
Inside the Pipeline
Opus Genetics, Inc. is a clinical-stage biopharmaceutical enterprise headquartered in Durham, North Carolina, focused on building gene therapies to restore vision and prevent blindness. Its pipeline includes early-stage candidates addressing inherited retinal diseases, such as OPGx-LCA5 in Phase 1/2 clinical trials alongside pre-clinical programs targeting various forms of retinal degeneration. The company employs 27 people and trades under the ticker IRD on the Nasdaq Capital Market.
What to Watch at Opus Genetics, Inc.
Investors are tracking upcoming clinical milestones and the company's next scheduled earnings report, slated for November 11, 2026. As the firm continues development on its diverse ophthalmic programs, market participants will monitor further updates from covering analysts and institutional filings.
Related Filing Alerts
Source: HC Wainwright's rating change on $IRD (Jun 17, 2026). Written by software, not financial advice. How we make alerts